GSK views CIIE as platform for expanding health impact in China
Print Edition
The global biopharma company GSK said it remains steadfast to continue to maximize treatment for patients and seek new formats of collaborative healthcare service in the country.
Its high expectations of the Chinese market remain unchanged, with new initiatives hoping to accelerate its footprint here.
Infectious diseases, immunology/respiratory diseases, oncology, and HIV are the four core therapeutic areas where GSK is demonstrating its latest progresses in research and the most cutting-edge innovation in the home market.
鈥淭he annual grand event opens up enormous opportunities for us to expand our health impact for innovative medicines and healthcare solutions and also injects strong confidence in our continued development in China. We remain motivated and dedicated to speeding up research and development work with the aim of benefiting an even larger group of customers and patients,鈥 said Cecilia Qi, vice president and general manager of GSK China.
鈥淐IIE鈥檚 signal of continuous opening up also echoes well with GSK鈥檚 commitment to further expand alliances in China for a brighter blueprint of the healthcare ecosystem in the country based on open partnership and integrated industry development,鈥 she added.
鈥淚n recent years, we鈥檝e also seen encouraging advancements to speed up the introduction of new medicines and the overall mature digital healthcare ecosystem, which in general benefits multinationals as well as domestic players,鈥 she noted.
It expects five new products and new indications to be unveiled in China in the next three years under its new corporate mission to 鈥渦nite science, technology, and talent to get ahead of disease together.鈥
Over the last few years, the company has profited from CIIE鈥檚 spillover effects, has effectively hastened the introduction of a number of 鈥渇irst-in-China鈥 and 鈥渂est-in-class鈥 products, and has been able to reach out to more Chinese patients as a result of the 鈥淐hina CIIE Speed.鈥
鈥淭here鈥檚 no doubt China has huge market potential, and we deeply relate to China鈥檚 pledge to pursue high-quality development, as we鈥檙e determined to introduce more innovative medicines to the local market,鈥 she said.
It wants to remain an active participant and contributor to China鈥檚 healthcare system.
GSK鈥檚 Shanghai office was officially accredited as a designated multinational regional headquarters by the Shanghai Commerce Commission last year, and the company intends to capitalize on the position and increase its investment in the country.
鈥淲e feel Shanghai鈥檚 unwavering stance of opening up and continuously improving the business environment, and we remain steadfast in keeping our China headquarters and research and development here.鈥
With approximately 70 global R&D projects going on, China is included in 90 percent of global simultaneous development projects.
GSK鈥檚 Vocabria (cabotegravir injection) was exhibited at last year鈥檚 CIIE. In October, it was approved to be used with Janssen Pharmaceuticals鈥 Rekambys (rilpivirine long-acting injection) to treat HIV-1 infection.
This regimen is the first long-acting injectable HIV treatment capable of replacing daily oral medications, offering the convenience of monthly or bimonthly dosing. It may provide new treatment choices for people infected with HIV who are experiencing difficulties with current medications.
GSK has long prioritized increasing access to medicines and vaccines in China.
Last month, GSK reached an exclusive agreement with Chongqing Zhifei Biological Products Co Ltd to co-promote Shingrix, GSK鈥檚 shingles vaccine, in China for an initial three-year period. The combined scale and expertise of the two parties are projected to greatly increase Shingrix availability, allowing for the rapid expansion of patient access to the vaccine and additional potential indications.
Zhifei have granted GSK the right of first refusal to be their exclusive partner for any co-development and commercialization of an RSV vaccine for older adults in China, paving the way for the companies to potentially partner on Arexvy upon approval in China.
鈥淲e will continue to pursue a wide range of initiatives to collaborate with all types of stakeholders, including hospitals, charitable foundations, and public health organizations, and explore new models of partnership to expand medical service and resources for the general public,鈥 said Beulah Ji, vice president and China head of development in GSK.
She added that the organization has seen a smoother procedure for introducing new research projects and pursuing local collaboration, and the progress accomplished during prior editions of CIIE has given it a lot of confidence to keep up the efforts.
The national approach and measures to combine disease prevention and treatment with an emphasis on primary healthcare are particularly encouraging, echoing the product portfolio of GSK that address people鈥檚 health needs throughout their entire lifecycles.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 娌狪CP璇侊細娌狪CP澶05050403鍙-1
- |
- 浜掕仈缃戞柊闂讳俊鎭湇鍔¤鍙瘉锛31120180004
- |
- 缃戠粶瑙嗗惉璁稿彲璇侊細0909346
- |
- 骞挎挱鐢佃鑺傜洰鍒朵綔璁稿彲璇侊細娌瓧绗354鍙
- |
- 澧炲肩數淇′笟鍔＄粡钀ヨ鍙瘉锛氭勃B2-20120012
Copyright 漏 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
